<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04200248</url>
  </required_header>
  <id_info>
    <org_study_id>RBM 007-002</org_study_id>
    <nct_id>NCT04200248</nct_id>
  </id_info>
  <brief_title>A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration</brief_title>
  <acronym>TOFU</acronym>
  <official_title>A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of RBM-007 Monotherapy and RBM-007 in Combination With Eylea® Compared to Eylea® Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ribomic USA Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ribomic USA Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, active-controlled, double masked study assessing the safety, efficacy
      and durability of four monthly intravitreal (IVT) injections of RBM-007 monotherapy, and four
      monthly RBM-007 injections in combination with Eylea® dosed at every other month, compared to
      Eylea® monotherapy dosed at every other month in approximately eighty-one subjects with
      exudative age-related macular degeneration (AMD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RBM-007 is a novel oligonucleotide-based aptamer having potent anti-FGF2 activity and
      anti-VEGF-expression activity
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity - continuous</measure>
    <time_frame>Week 16</time_frame>
    <description>Mean change in Best Corrected Visual Acuity from Baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity - categorical</measure>
    <time_frame>Week 16</time_frame>
    <description>Proportion of patients gaining more than 15 letters as measured by Best Corrected Visual Acuity from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macular thickness change</measure>
    <time_frame>Week 16</time_frame>
    <description>Change from Baseline in Central Subfield Thickness by spectral domain optical coherence tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macular volume change</measure>
    <time_frame>Week 16</time_frame>
    <description>Change from Baseline in macular volume by spectral domain optical coherence tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis change</measure>
    <time_frame>Week 16</time_frame>
    <description>Change from Baseline in sub-retinal hyper-reflective material by spectral domain optical coherence tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Ocular</measure>
    <time_frame>Week 20</time_frame>
    <description>Ocular examination (biomicroscopy and ophthalmoscopy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Systemic - Heart rate</measure>
    <time_frame>Week 20</time_frame>
    <description>Change in heart rate (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Systemic - Blood pressure</measure>
    <time_frame>Week 20</time_frame>
    <description>Change in systolic and diastolic blood pressure (millimeters of mercury)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Exudative Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Sham + RBM-007</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sham + RBM-007 intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RBM-007 + Aflibercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RBM-007 + Aflibercept intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham + Aflibercept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sham + Aflibercept intravitreal injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBM-007 Injectable Solution</intervention_name>
    <description>RBM-007 Injectable Solution</description>
    <arm_group_label>RBM-007 + Aflibercept</arm_group_label>
    <arm_group_label>Sham + RBM-007</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>EYLEA® (aflibercept) Injection, for Intravitreal Use</description>
    <arm_group_label>RBM-007 + Aflibercept</arm_group_label>
    <arm_group_label>Sham + Aflibercept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Sham intravitreal injection</description>
    <arm_group_label>Sham + Aflibercept</arm_group_label>
    <arm_group_label>Sham + RBM-007</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provide signed written informed consent.

          2. Male or female 55 years of age or older on the date of signing the consent and able
             and willing to comply with all treatment and study procedures.

          3. Diagnosis of exudative age-related macular degeneration in the study eye, for which
             previous standard treatment with intravitreal anti-vascular endothelial growth factor
             agents (at least 4 injections over the past 8 months) has demonstrated incomplete
             resolution of exudation, as assessed by spectral domain optical coherence tomography.

          4. Presence of macular edema or subretinal fluid.

          5. Absence of central atrophy or retinal epithelial tear in the fovea or any condition
             preventing visual acuity improvement in the study eye.

          6. Visual acuity of 78 to 24 letters (20/32 to 20/320) in the study eye.

          7. Visual acuity of 24 letters (20/320) or better in the fellow eye.

          8. Reasonably clear media and some fixation in the study eye to allow for good quality
             tomography and fundus photography

        Exclusion Criteria:

          -  Ocular:

               1. Use of any of the following treatments or anticipated use of any of the following
                  treatments to the study eye:

                    1. Any intravitreal treatment within 4 weeks prior to Baseline (Visit 1).

                    2. Intravitreal or periocular corticosteroid, within 90 days prior to Visit 1
                       (Day 1) and throughout the study.

                    3. Fluocinolone acetonide intravitreal implant, within 12 months prior to Visit
                       1 (Day 1) and throughout the study.

                    4. Visudyne® photodynamic therapy, within 90 days prior to Visit 1 (Day 1) and
                       throughout the study.

               2. Uncontrolled or advanced glaucoma, evidenced by an intraocular pressure of &gt; 21
                  mmHg or cup/disc ratio &gt; 0.8 while on medical therapy, or chronic hypotony (&lt; 6
                  mmHg) in the study eye.

               3. Evidence of any other ocular disease other than wet age-related macular
                  degeneration in the study eye that may confound the outcome of the study

               4. History of vitrectomy in the study eye.

               5. Need for ocular surgery in the study eye during the course of the study.

               6. YAG laser capsulotomy within 30 days prior to Visit 1 (Day 1) in the study eye.

               7. Intraocular surgery, including lens removal or laser, within 90 days prior to
                  Visit 1 (Day 1) in the study eye.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yusuf Ali, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Ribomic USA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yusuf Ali, Ph.D.</last_name>
    <phone>(707) 287-4313</phone>
    <email>yusuf.ali@ribomic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Pereira, M.D.</last_name>
    <phone>(415) 341-4996</phone>
    <email>daniel.pereira@ribomic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Retinal Consultants Medical Group</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95841</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mia Katz</last_name>
      <phone>916-339-2693</phone>
      <email>katzm@retinalmd.com</email>
    </contact>
    <investigator>
      <last_name>Joel Pearlman, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bay Area Retina Associates</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Manz</last_name>
      <phone>925-943-6800</phone>
      <email>smanz@bayarearetina.com</email>
    </contact>
    <investigator>
      <last_name>Subhransu Ray, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Raj K. Maturi, M.D., P.C.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinaya Mahesh</last_name>
      <phone>317-805-2198</phone>
      <email>vinayam@midwesteye.com</email>
    </contact>
    <investigator>
      <last_name>Raj K Maturi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Valley Retina Institute, PA</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yesina Salinas</last_name>
      <phone>956-631-8875</phone>
      <phone_ext>157</phone_ext>
      <email>ysalinas@vritx.com</email>
    </contact>
    <investigator>
      <last_name>Victor H. Gonzalez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center Ophthalmology Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muayad Maalah</last_name>
      <phone>210-697-2036</phone>
      <phone_ext>2278</phone_ext>
      <email>muayad@mcoaeyecare.com</email>
    </contact>
    <investigator>
      <last_name>Michael A Singer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 8, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2019</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fibrosis</keyword>
  <keyword>Edema</keyword>
  <keyword>Neovascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

